Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin adjunctive therapy for primary generalized tonic-clonic seizures
NL-OMON41642Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pregabalin in epilepsy and generalized tonic-clonic seizure (GTCS) (3 arms), sponsored by Pfizer. Primary endpoint: Primary efficacy endpoint. Planned start May 2013; status: withdrawn.
02
Drugs
pregabalin
03
Conditions
epilepsygeneralized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on NL-OMON41642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41642.